PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Crizotinib fails to improve disease-free survival in resected early-stage ALK+ NSCLC

2025-09-07
(Press-News.org) (Barcelona, Spain September 7, 2025, 10:45 a.m. CEST / UTC +2 ) — Crizotinib, an approved treatment for advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC), did not improve disease-free survival (DFS) when given as adjuvant therapy in patients with surgically resected early-stage ALK+ NSCLC, according to results from the Phase 3 E4512 trial presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC).

The trial, conducted within the ALCHEMIST clinical trials program, enrolled patients with resected stage IIA–IIIB (AJCC 8th edition) ALK+ NSCLC confirmed by FISH, IHC, or NGS. Eligible patients had negative surgical margins, an ECOG performance status of 0–1, and no prior ALK inhibitor therapy. Adjuvant chemotherapy and post-operative radiation therapy were permitted.

David Gerber, MD, a medical oncologist at the UT Southwestern Harold C. Simmons Comprehensive Cancer Center, and colleagues randomized patients to receive observation or crizotinib 250 mg twice daily for up to two years, or until disease recurrence or unacceptable toxicity. The primary endpoint was DFS, with secondary endpoints of overall survival (OS) and safety.

Between August 2014 and May 2024, 166 patients (of 168 planned) were enrolled (92% confirmed centrally as ALK+). Enrollment was stopped after the U.S. Food and Drug Administration approved adjuvant alectinib for resected ALK+ NSCLC.  

At a median follow-up of 58.3 months the study found that:

- Median DFS was 72.8 months for crizotinib vs. 75.1 months for observation (HR 1.06; 90% CI, 0.63–1.77; P=0.86).
- Median OS was not reached in either arm (HR 0.49; 90% CI, 0.18–1.37; P=0.26).
- Grade 3 treatment-related adverse events occurred in 34% of patients receiving crizotinib, most commonly diarrhea (6%) and edema (4%); one patient experienced a grade 4 event (stroke).
- 22% of patients required dose reductions and 25% discontinued treatment due to toxicity.

“Adjuvant crizotinib does not prolong disease-free survival in resected ALK+ NSCLC,” said Dr. Gerber.

About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 10,000 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies. Visit www.iaslc.org for more information.

About the WCLC:
The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting nearly 7,000 researchers, physicians, and specialists from more than 100 countries. The goal is to increase awareness, collaboration and understanding of lung cancer, and to help participants implement the latest developments across the globe. The conference covers a wide range of disciplines and unveils several research studies and clinical trial results. For more information, visit https://wclc.iaslc.org/.

END


ELSE PRESS RELEASES FROM THIS DATE:

Ivonescimab plus chemotherapy improves progression-free survival in patients with EGFR+ NSCLC following 3rd-generation EGFR-TKI therapy

2025-09-07
Ivonescimab Plus Chemotherapy Improves Progression-Free Survival in Patients with EGFR+ NSCLC Following 3rd-Generation EGFR-TKI Therapy (Barcelona, Spain September 7, 2025, 10:45 a.m. CEST / UTC +2) — Adding ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, to chemotherapy significantly prolonged progression-free survival (PFS) compared to chemotherapy alone in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR mutations whose disease progressed on third-generation EGFR tyrosine kinase inhibitors (TKIs). Results from the global Phase 3 HARMONi trial were presented today by Jonathan ...

FLAURA2 trial shows osimertinib plus chemotherapy improves overall survival in eGFR-mutated advanced NSCLC

2025-09-07
(Barcelona, Spain September 7, 2025, 10:45 a.m. CEST / UTC +2) Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC). These findings, presented today at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer, support osimertinib plus chemotherapy as a new standard-of-care ...

Aumolertinib plus chemotherapy improves progression-free survival in NSCLC with EGFR and concomitant tumor suppressor genes: ACROSS 2 phase III study

2025-09-07
Contact: Chris Martin, MPH IASLC Media Relations cmartin@davidjamesgroup.com (Barcelona, Spain September 7, 2025, 10:45 a.m. CEST / UTC +2) – New results from the ACROSS 2 Phase III trial demonstrate that aumolertinib combined with platinum-pemetrexed chemotherapy significantly improves progression-free survival compared to aumolertinib monotherapy in patients with advanced/metastatic non-small cell lung cancer (NSCLC) harboring EGFR sensitizing mutations and concomitant tumor suppressor gene mutations. The results were presented by Dr. Jie Wang, National Cancer Center, ...

New antibody-drug conjugate shows promising efficacy in EGFR-mutated NSCLC patients

2025-09-06
Contact: Chris Martin, MPH/IASLC Media Relations/cmartin@davidjamesgroup.com (Barcelona, Spain — September 6, 2025, 5:45 p.m. CEST / UTC +2 ) — A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), demonstrated encouraging safety and efficacy results in previously treated patients with EGFR-mutated non-small cell lung cancer (NSCLC), according to findings presented at the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer (WCLC). Iza-bren is a first-in-class EGFR x HER3 bispecific ADC linked to a novel topoisomerase I inhibitor payload (Ed-04). The drug was evaluated ...

Iza-Bren in combination with osimertinib shows 100% response rate in EGFR-mutated NSCLC, phase II study finds

2025-09-06
Iza-Bren in combination with Osimertinib Shows 100% Response Rate in EGFR-Mutated NSCLC, Phase II Study Finds Barcelona, Spain (September, 2025) —A combination of iza-bren (BL-B01D1), a novel bispecific antibody-drug conjugate (ADC), with osimertinib demonstrated a 100% objective response rate (ORR) in patients with first-line EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC). This study was presented today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC). Iza-bren is a first-in-class ADC combining EGFR and HER3 targeting with a topoisomerase I inhibitor payload. The study tested iza-bren at multiple ...

COMPEL study shows continuing osimertinib treatment through progression with the addition of chemotherapy improves progression-free survival in EGFR-mutated NSCLC

2025-09-06
(Barcelona, Spain September 6, 2025, 5:45 p.m. CEST / UTC +2 ) — A new analysis from the COMPEL trial shows that patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) who experienced non-central nervous system (CNS) progression on first-line osimertinib benefit from continuing osimertinib treatment in combination with platinum-based chemotherapy. The study was presented today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC). The COMPEL study is a global, randomized, double-blind trial, in which adult patients with non-CNS progression on first-line osimertinib were randomized 1:1 to receive either osimertinib ...

CheckMate 77T: Nivolumab maintains quality of life and reduces symptom deterioration in resectable NSCLC

2025-09-06
(Barcelona, Spain September 6, 2025, 5:45 p.m. CEST / UTC +2 ) — An analysis from the Phase 3 CheckMate 77T trial confirms that perioperative nivolumab does not compromise health-related quality of life (HRQoL) in patients with resectable non-small cell lung cancer (NSCLC), including those with Stage III N2 disease. These results were presented today at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC). The study assessed HRQoL by nodal status and surgical outcomes using patient-reported outcome (PRO) measures such as the NSCLC-Symptom Assessment Questionnaire (NSCLC-SAQ) and the EQ-5D-3L visual ...

Study validates AI lung cancer risk model Sybil in predominantly Black population at urban safety-net hospital

2025-09-06
(Barcelona, Spain September 6, 2025, 5:45 p.m. CEST / UTC +2 ) — A new study presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC) validates the use of Sybil, a deep learning artificial intelligence model, for predicting future lung cancer risk in a predominantly Black population. The study, conducted by the University of Illinois Hospital & Clinics, (UI Health), the academic health enterprise of the University of Illinois Chicago (UIC), highlights Sybil’s strong performance in a real-world clinical setting with racially and socioeconomically ...

New medication lowered hard-to-control high blood pressure in people with chronic kidney disease

2025-09-06
Research Highlights: Results from the FigHTN Phase 2 clinical trial showed baxdrostat, a new medication that inhibits the production of the hormone aldosterone, lowered systolic blood pressure by about 5% when added to the existing medications taken by people with chronic kidney disease and who also have uncontrolled high blood pressure. The analysis also found that baxdrostat lowered the loss of albumin in the urine, which is a marker of kidney and cardiovascular risk, by 55% compared to placebo, suggesting that this medication may help delay the progression of kidney disease . These findings suggest the potential for baxdrostat to improve longer-term health outcomes like kidney and ...

Innovative oncolytic virus and immunotherapy combinations pave the way for advanced cancer treatment

2025-09-05
  The integration of oncolytic viruses (OVs) with immunotherapy is reshaping the landscape of tumor treatment, offering new hope for patients. This cutting-edge approach harnesses the ability of OVs to selectively infect and destroy tumor cells, while simultaneously stimulating anti-tumor immune responses. The latest advancements in genetic engineering have further optimized these therapies, leading to improved clinical outcomes and enhanced patient quality of life.   By combining OVs with cellular immunotherapy, immune checkpoint inhibitors, cancer vaccines, cytokines, and bi- or tri-specific T cell engagers, researchers have developed innovative ...

LAST 30 PRESS RELEASES:

AI ECG better detects severe heart attacks in emergency setting

Straw-based biochar and smart irrigation help maize thrive with less water and fertilizer

‘Broken’ genes a common factor in marsupial fur colour

Turning waste into clean water: Magnetic carbon materials remove toxic pollutants from wastewater

World Health Organization’s priorities shaped by its reliance on grants from donor organisations such as the Gates Foundation

One in ten people without coeliac disease or wheat allergy report sensitivity to gluten or wheat

How can (A)I help you?

Study finds new system can cut patient waiting times for discharge

Allison Institute’s third annual scientific symposium highlighted by panel discussion with five Nobel laureates

SETI Institute accelerates the search for life beyond earth with NVIDIA IGX Thor

Wetlands efficiently remove nitrogen pollution from surface water, leading to cost savings for municipalities

Dr. Loren Miller presents oral late breaker at IDWeek 2025 of a first-of-its-kind clinical trial that shows efficacy of bacteriophage therapy for Staphylococcus aureus bacteremia

Dirty water boosts prospects for clean hydrogen

New multisociety guidance strengthens infection prevention and control in nursing homes

More scientific analysis needed on impacts of industrial decarbonization

New research uncovers how bad bacteria know where to cluster and cause infection

As ochre sea star ‘baby boomers’ grow up, species showing signs of recovery

Six-million-year-old ice discovered in Antarctica offers unprecedented window into a warmer Earth

When it comes to mating, female mosquitoes call the shots

CZI and NVIDIA accelerate virtual cell model development for scientific discovery

JMIR Publications and MCBIOS partner to boost open access bioinformatics research

Canadian scientists describe an extinct rhino species from Canada's High Arctic

Houseplant inspires textured surfaces to mitigate copper IUD corrosion

LIGO, Virgo and KAGRA observed “second generation” black holes

Dicer: Life's ancient repair tool

Environmental shifts are pushing endangered reptiles to the brink of extinction

New open-source American College of Lifestyle Medicine program brings culinary skills and nutrition education into medicine

AI tool identifies women at high risk of interval breast cancer

USF study: AI and citizen science reveal potential first detection of invasive malaria mosquito in Madagascar

American Pediatric Society honors Dr. Bruce D. Gelb with 2026 APS John Howland Award

[Press-News.org] Crizotinib fails to improve disease-free survival in resected early-stage ALK+ NSCLC